Form 4: Precigen Director Randal Kirk Boosts Stake

Precigen Director and 10% owner Randal J. Kirk acquired additional common stock, restricted stock units, and stock options, increasing his beneficial ownership.

Summary

• Randal J. Kirk, a Director and 10% owner of Precigen, Inc. (PGEN), acquired additional securities on March 10, 2026.
• He acquired 28,490 shares of common stock at a price of $3.51 per share.
• He was granted 71,225 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock, vesting on the one-year anniversary of the grant date (March 10, 2027), subject to continuous service.
• He was also granted options to purchase 82,147 shares of common stock with an exercise price of $3.51 per share, exercisable immediately and expiring on March 10, 2036.
• Following these transactions, Mr. Kirk's total beneficial ownership of common stock, including indirect holdings through various entities he controls and his spouse, amounts to 122,074,674 shares.
• Additionally, he beneficially owns 71,225 Restricted Stock Units and options to purchase 82,147 shares of common stock.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, reflecting significant insider confidence and a long-term commitment from a key director and major shareholder, which typically bodes well for future performance.

Positives

• A Director and 10% owner, Randal J. Kirk, acquired 28,490 shares of common stock at $3.51 per share, signaling confidence in the company's valuation.
• The grant of 71,225 Restricted Stock Units and 82,147 stock options aligns management's incentives with long-term shareholder value creation.
• The significant total beneficial ownership of 122,074,674 common shares by a key insider demonstrates a strong vested interest in the company's success.

Risks

• The vesting of Restricted Stock Units is contingent on Mr. Kirk continuously providing services to the issuer or an affiliate, introducing a dependency on his continued involvement.
• Mr. Kirk disclaims beneficial ownership of shares held by controlled entities, except to the extent of any pecuniary interest, which could imply a complex ownership structure.

Future Outlook

The filing indicates future vesting of Restricted Stock Units on March 10, 2027, contingent on Mr. Kirk's continuous service, and options exercisable until March 10, 2036, suggesting a long-term commitment.

Management Comments

• Randal J. Kirk controls each of R.J. Kirk Declaration of Trust and various other entities. Shares held by these entities may be deemed to be beneficially owned by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
• Each restricted stock unit represents a contingent right to receive one share of issuer common stock and shall vest on the one-year anniversary of the date of grant, subject to Mr. Kirk continuously providing services to the issuer or an affiliate from the date of grant until such time.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a director and significant owner, is generally viewed positively by the market as it signals management's confidence in the company's future prospects and intrinsic value. The grant of equity awards is a common practice to align executive interests with shareholder returns in the biotechnology sector.

Comparison to Industry Standards

• Insider purchases and equity grants are standard practices across industries, including biotechnology. While specific comparable companies or projects are not detailed in this filing, a director increasing their stake, especially a 10% owner, often outperforms general market sentiment for similar-sized companies in the short to medium term.
• For instance, studies by academic institutions like the Wharton School have shown that clusters of insider buying can precede periods of outperformance relative to industry peers.

Related Party Transactions

• Randal J. Kirk controls multiple entities (e.g., R.J. Kirk Declaration of Trust, JPK LLCs, MGK LLCs, ZSK LLCs, Kellie L. Banks LTT, Kapital Joe, Lotus Capital, Third Security, Parkview 2020, Sunset 2020) through which he indirectly beneficially owns a significant portion of Precigen's common stock.
• Shares are also indirectly beneficially owned by his spouse.

Stakeholder Impact

• Shareholders: The transactions signal strong insider confidence, which could positively influence investor sentiment and potentially the stock price. The alignment of management incentives through equity grants benefits long-term shareholders.
• Employees: The continued involvement and commitment of a key director like Randal J. Kirk can provide stability and strategic direction.

Next Steps

• Vesting of 71,225 Restricted Stock Units on March 10, 2027, subject to continuous service.
• Potential exercise of 82,147 stock options at $3.51 per share until March 10, 2036.

Key Dates

Recommendation

The significant acquisition of common stock by a director who is also a 10% owner, coupled with substantial equity grants (RSUs and options), demonstrates a high level of conviction in Precigen's future. This strong insider buying, especially from a major stakeholder, is a powerful indicator of potential future outperformance and aligns management's interests directly with shareholder value, making it a compelling 'strong buy' signal for seasoned investors.

Keywords

Precigen, PGEN, Randal J. Kirk, Insider Trading, Form 4, Stock Acquisition, Restricted Stock Units, Stock Options, Beneficial Ownership, Director, 10% Owner, Biotechnology, SEC Filing